Intravitreal Corticosteroids: Ensuring Effective Use With IOP Control
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Overview
This continuing medical education (CME) activity captures content from a roundtable discussion held in May of 2016 in Seattle, Washington.Jointly provided by Evolve Medical Education LLC, New Retina MD, and Retina Today. Supported through an educational grant by Allergan. Learning Objectives
Upon completion of this activity, the participant should be able to:
- Identify risk factors associated with rises in IOP after steroid use
- Discuss management strategies for patients who experience rises in IOP after steroid use
- Assess clinical trial data pertaining to steroid implant therapies, including MEAD, FAME, BEVORDEX and OMAR
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, Retina Today, and New Retina MD. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Michael A. Singer, MD, moderator Medical Center Ophthalmology Associates San Antonio, Texas
Maria H. Berrocal, MD Berrocal & Associates San Juan, Puerto Rico
Tarek S. Hassan, MD Associated Retinal Consultants Royal Oak, Michigan
Andrew A. Moshfeghi, MD, MBA Keck School of Medicine Los Angeles, California
Gaurav K. Shah, MD The Retina Institute St. Louis, Missouri
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Michael A. Singer, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Genentech; and Regeneron Pharmaceuticals. Grant/Research Support: Aerpio Therapeutics; Allergan; Ampio Pharmaceuticals; Genentech; Ohr Pharmaceutical; and Regeneron Pharmaceuticals.
Maria H. Berrocal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; and Allergan. Stock/Shareholder: Hemera.
Tarek S. Hassan, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Bausch + Lomb; Eyetech Pharmaceuticals; Genentech; Insight Instruments; Regeneron Pharmaceuticals; and ThromboGenics NV. Patent Holder: Insight Instruments. Stock/Shareholder: ArcticDx and OptiMedica.
Andrew A. Moshfeghi, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Genentech; and Regeneron Pharmaceuticals. Grant/Research Support: Genentech and Regeneron Pharmaceuticals.
Gaurav K. Shah, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Bausch + Lomb; QLT; Regeneron Pharmaceuticals.
Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Emily Feinman, administrator, BMC; Bryan Bechtel, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Allergan.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!